Abstract

A previous in vitro study showed that sphingosine-1-phosphate (S1P), a ceramide antagonist, preserved endothelial cells in culture from radiation-induced apoptosis. We proposed to validate the role of S1P in tissue radioprotection by inhibiting acute gastrointestinal (GI) syndrome induced by endothelial cell apoptosis after high dose of radiation. Retro-orbital S1P was injected in mice exposed to 15 Gy, a dose-inducing GI syndrome within 10 days. Overall survival and apoptosis on intestines sections were studied. Intestinal cell type targeted by S1P and early molecular survival pathways were researched using irradiated in vitro cell models and in vivo mouse models. We showed that retro-orbital S1P injection before irradiation prevented GI syndrome by inhibiting endothelium collapse. We defined endothelium as a specific therapeutic target because only these cells and not intestinal epithelial cells, or B and T lymphocytes, were protected. Pharmacologic approaches using AKT inhibitor and pertussis toxin established that S1P affords endothelial cell protection in vitro and in vivo through a mechanism involving AKT and 7-pass transmembrane receptors coupled to Gi proteins. Our results provide strong pharmacologic and mechanistic proofs that S1P protects endothelial cells against acute radiation enteropathy.

Highlights

  • Research has shed new light on the critical role of microvasculature collapse in tissue pathology induced by genotoxic stresses [1]

  • S1P rescues mice from radiation-induced GI syndrome The ability of S1P to protect mice from radiation-induced death was estimated by overall survival

  • Irradiated animals died from BM aplasia after S1P-injection instead of GI syndrome after sham treatment

Read more

Summary

Introduction

Research has shed new light on the critical role of microvasculature collapse in tissue pathology induced by genotoxic stresses [1]. A notable, but controversial, example is the involvement of microvascular endothelium in the early response to radiation. The gastrointestinal (GI) syndrome, an acute adverse effect of radiotherapy, has long been considered to be dependent solely on the dysfunction of the intestinal clonogenic compartment [2, 3]. Authors' Affiliations: 1Inserm UMR892-Centre de Recherche en Cancerologie Nantes-Angers, Nantes, France; 2Centre de Lutte Contre le Cancer Nantes-Atlantique, Saint-Herblain, France; 3Radiation Oncology Department, Memorial Sloan-Kettering Cancer Center, New York, New York; 4Institut de Radioprotection et de Sûrete Nucleaire, Fontenay-auxRoses, France; and 5Laboratory of Signal Transduction, Sloan-Kettering Institute, New York, New York. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call